Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.eBioscience Takes Over Bender MedSystems
eBioscience has acquired Bender MedSystems in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA
eBioscience has acquired Bender MedSystems in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA
GeneNews has entered into an agreement allowing Eli Lilly select access to research from its osteoarthritis genomic biomarker program. Terms of the agreement were not disclosed. Heiner Dreismann,
Ingenuity Systems has developed a new gene expression workflow with Life Technologies. The workflow leverages Ingenuity’s IPA software, the Applied Biosystems SOLiD System, TaqMan Gene Expression Assays and
Mediware Information Systems has announced that the Blood Bank of Alaska is the latest blood center to license LifeTrak, the company’s 510(k) cleared blood donor management software. Using
Halozyme Therapeutics (Halozyme) and Roche have reported dosing of the first patient in a phase 3 registration trial using Enhanze technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous
ZyGEM and Phthisis Diagnostics have entered into an agreement to develop products enabling the detection of infectious pathogens in complex samples, such as stool, blood and water. Reportedly,
The scientists at GE Global Research and researchers at Eli Lilly have reported a positive advancement in cancer research resulting from the two companies’ collaboration formed in October
Kinaxo Biotechnologies (Kinaxo) has entered into a collaboration with Roche Diagnostics in Penzberg, Germany. Under the agreement Kinaxo’s phosphoproteomics technology PhosphoScout will be applied to support the identification
Protein Discovery and New Objective have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry
Emisphere Technologies has reported that a single dose of the novel oral parathyroid hormone PTH1-34 has achieved potentially therapeutically relevant exposure and safety profiles to those of the